{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T17:19:37Z","timestamp":1777742377801,"version":"3.51.4"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have become an important part of malignant tumor therapy. However, some adverse reactions follow ICIs therapy. The incidence of immune-mediated colitis (IMC) has also increased. Here, the case of a 67-year-old male patient with stage IVB esophagogastric junction squamous cell carcinoma after chemotherapy, targeted therapy and immunotherapy is presented. This patient underwent treatment with six courses of protein-bound paclitaxel + cis-platinum+ sintilimab, followed by maintenance therapy with sintilimab alone. The patient developed intestinal obstruction, abdominal pain, hemorrhage of the lower digestive tract and other discomfort and was diagnosed with multiple jejunal ulcers via colonoscopy and pathological biopsy. The aims of presenting this case report are to improve clinicians\u2019 understanding of and ability to treat sintilimab-related adverse reactions and to more scientifically and rationally administer sintilimab for the treatment of malignant tumors.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1590714","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:38:19Z","timestamp":1753940299000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Sintilimab-induced intestinal obstruction and hemorrhage of the digestive tract: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Qian","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuxiu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghua","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190850","article-title":"An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ Clin Res Ed"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1343020","article-title":"Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies","volume":"15","author":"Soussan","year":"2024","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Sci (New York NY)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: A promising anti-tumor PD-1 antibody","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.03.001","article-title":"Microbiome and anticancer immunosurveillance","volume":"165","author":"Zitvogel","year":"2016","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae Insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-2501","article-title":"Immune checkpoint inhibitor-induced colitis complicated with inflammatory intestinal obstruction: a case report and literature review","volume":"11","author":"Tan","year":"2022","journal-title":"Trans Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i29.10550","article-title":"Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports","volume":"10","author":"Zhang","year":"2022","journal-title":"World J Clin Cases"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1121122","article-title":"Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report","volume":"14","author":"Ni","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1590714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:38:19Z","timestamp":1753940299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1590714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2025.1590714"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1590714","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"article-number":"1590714"}}